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Activation of the inflammasome generates the pro-inflamma-
tory cytokines interleukin-1 and -18, which are important
mediators of inflammation. Abnormal activation of the inflam-
masome leads to many inflammatory diseases, including gout,
silicosis, neurodegeneration, and genetically inherited periodic
fever syndromes. Therefore, identification of small molecule
inhibitors that target the inflammasome is an important step
toward developing effective therapeutics for the treatment of
inflammation. Here, we show that the herbal NF-B inhibitory
compound parthenolide inhibits the activity ofmultiple inflam-
masomes in macrophages by directly inhibiting the protease
activity of caspase-1. Additional investigations of other NF-B
inhibitors revealed that the synthetic IBkinase- inhibitor Bay
11-7082 and structurally related vinyl sulfone compounds selec-
tively inhibit NLRP3 inflammasome activity in macrophages
independent of their inhibitory effect onNF-B activity. In vitro
assays of the effect of parthenolide and Bay 11-7082 on the
ATPase activity of NLRP3 demonstrated that both compounds
inhibit the ATPase activity of NLRP3, suggesting that the inhib-
itory effect of these compounds on inflammasome activity could
be mediated in part through their effect on the ATPase activity
of NLRP3. Our results thus elucidate the molecular mechanism
for the therapeutic anti-inflammatory activity of parthenolide
and identify vinyl sulfones as a new class of potential therapeu-
tics that target the NLRP3 inflammasome.
The inflammasome collectively refers to oligomeric molecu-
lar platforms or assemblies that recruit and activate caspase-1
(1), which processes inactive pro-IL-13 and pro-IL-18 into the
active pro-inflammatory cytokines IL-1 and IL-18, respec-
tively (2, 3). These assemblies are formed in the cytoplasm of
innate immune cells in response to danger signals (1). The
NLRP3 (cryopyrin, NALP3) inflammasome (4) is particularly
important because it is activated by diverse signals, including
bacteria, viruses, purified microbial products, components of
dying cells, small molecule immune activators, and crystalline
or aggregated materials (1). Inappropriate activation of the
NLRP3 inflammasome has been implicated in the pathogenesis
of a number of human diseases, including gouty arthritis, sili-
cosis, and neurodegeneration (5–8). In addition, abnormal
activation of the NLRP3 inflammasome due to mutations in
NLRP3 is responsible for several autoinflammatory diseases
(9–12). Consequently, identification of small molecule inhibi-
tors of the NLRP3 inflammasome is important for understand-
ing its mechanism of activation and for the design of effective
therapeutics for the treatment of inflammasome-associated
diseases.
Here, we demonstrate that the NF-B pathway inhibitors
parthenolide and Bay 11-7082 are potent inhibitors of the
inflammasome independent of their inhibitory effect on the
NF-Bpathway.We show that parthenolide is a direct inhibitor
of caspase-1 and NLRP3, whereas Bay 11-7082 and several
structurally related vinyl sulfone compounds are selective
inhibitors of NLRP3. This study identifies parthenolide as the
first natural product that directly targets caspase-1 and the
NLRP3 inflammasome and vinyl sulfones as the first small mol-
ecules that selectively inhibit activation of the NLRP3 inflam-
masome, possibly by targeting its ATPase activity. The ability of
vinyl sulfones to cross the cell membrane and inhibit the
NLRP3 inflammasome in macrophages should enable future
development of related compounds as anti-inflammatory ther-
apeutics for the treatment of inflammatory diseases and the
development of vinyl sulfone-based probes to investigate the
mechanism of activation of the NLRP3 inflammasome in
macrophages.
EXPERIMENTAL PROCEDURES
Antibodies and Reagents—The anti-IL-1 monoclonal anti-
body (32D) was obtained from the NCI Preclinical Repository,
Biological Resources Branch. Antibodies against human
caspase-1 p30 (polyclonal anti-human caspase-1, residues
100–404; our laboratory), mouse NLRP3 (polyclonal anti-
NLRP3 PYD; our laboratory), mouse ASC (polyclonal anti-
mouse ASC; from Dr. Junji Sagara), and mouse caspase-1 p20
* Thisworkwas supported, inwholeor inpart, byNational Institutes ofHealth
Grants AG14357 and AR055398 (to E. S. A.) and Grants 1R01AI083713 and
R01HL093262 (to E. L.).
□S The on-line version of this article (available at http://www.jbc.org) contains
supplemental “Experimental Procedures” and Figs. 1–6.
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dimethyl sulfoxide; LDH, lactate dehydrogenase; IKK, IB kinase-;
MSU, monosodium urate; IMPSPN, (E)-2-iodo-3-(4-methylphenyl)sulfo-
nylprop-2-enenitrile; MBSPN, 3-[(4-methylbenzene)sulfonyl]propane-
nitrile; CPSMB, 1-(3-chloroprop-1-enylsulfonyl)-4-methylbenzene; ESMB,
1-(ethenylsulfonyl)-4-methylbenzene; PV, phenyl vinyl.
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(monoclonal anti-mouse caspase-1 p20; from Dr. Junying
Yuan) were described previously (13–15). Anti-FLAGM2-aga-
rose affinity gel, polyethyleneimine-cellulose TLC plates, ATP,
nigericin, 1-(3-chloroprop-1-enylsulfonyl)-4-methylben-
zene, phenyl vinyl sulfide, phenyl vinyl sulfone, phenyl vinyl
sulfonate, and glutathione were from Sigma. Parthenolide, Bay
11-7082, Bay 11-7085, CA-074-Me, and E-64 were from
BIOMOL. MG132 was from Calbiochem. IMD0354 and
SC514 were from Tocris. Ultrapure LPS was from InvivoGen.
Anthrax lethal factor and protective antigen were from List
Biological Laboratories. Disuccinimidyl suberate was from
Thermo Fisher Scientific. 3-[(4-Methylbenzene)sulfonyl]pro-
panenitrile was from Enamine. [-32P]ATP (3000 Ci/mmol)
was from PerkinElmer Life Sciences. 1-(Ethenylsulfonyl)-4-
methylbenzene and (E)-2-iodo-3-(4-methylphenyl)sulfonyl-
prop-2-enenitrile were from the Developmental Therapeutics
Program at NCI, National Institutes of Health.
Cell Culture andGeneration of StableNG5Cell Line—Mouse
bone marrow cells were isolated frommouse femurs with ster-
ile Dulbecco’s modified Eagle’s medium (Invitrogen) and cul-
tured in 6-well plates for 5–7 days in Dulbecco’s modified
Eagle’s medium supplemented with 10% L929 cell-conditioned
medium, 10% fetal bovine serum, and 1% penicillin/streptomy-
cin. The differentiatedmacrophages were treated with or with-
out ultrapure LPS (500 ng/ml) in serum-free Opti-MEM I
medium for 5 h and subsequently treatedwith drugs for 15min,
followed by NLRP3 stimuli as indicated. The immortalized
Nlrp3/ macrophages were grown in Dulbecco’s modified
Eagle’smedium supplementedwith 10% fetal bovine serum and
100 units/ml penicillin and streptomycin. The stable NLRP3-
reconstituted NG5 cell line, which expresses a C-terminally
FLAG-tagged mouse NLRP3 protein, was generated by infect-
ing immortalizedNlrp3/macrophages with the pMSCVgfp-
mNLRP3-FLAG retroviral vector as described previously (14).
All cells were grown at 37 °C and 5% CO2.
Immunoblot Analysis of Active Caspase-1—Cell culture
supernatants from treated macrophages were precipitated and
analyzed by immunoblotting as described (16).
In Vitro Caspase-1 Activation and IL-1 Cleavage Assays—
Hypotonic THP-1 cell lysates were prepared in CHAPS buffer
(20mMHEPES-KOH, pH7.5, 5mMMgCl2, 0.5mMEGTA, 0.1%
CHAPS, 0.1 mM phenylmethylsulfonyl fluoride, and protease
inhibitormixture) as described (17). Cell lysateswere incubated
in the presence or absence of Bay 11-7082 (12 M) or parthe-
nolide (10 M) at 37 °C for 60 min. The lysates were then ana-
lyzed by SDS-PAGE, followed by immunoblotting with anti-
human caspase-1 p30 antibody. In some experiments, purified
ASC pyroptosomes were incubated with FLAG-tagged pro-
caspase-1 and pro-IL-1 in CHAPS buffer in the presence or
absence of parthenolide at 37 °C for 60 min as described previ-
ously (17). The reaction mixtures were then fractionated by
SDS-PAGE and analyzed by Western blotting with anti-FLAG
and anti-IL-1 antibodies.
To assess the effect of parthenolide on caspase-1 activity,
recombinant active caspase-1 was purified from a 293T-FLAG-
caspase-1 stable cell line by immunoprecipitation with anti-
FLAG antibody-agarose. Purified caspase-1 was incubatedwith
pro-IL-1 in CHAPS buffer in the absence or presence of
increasing concentrations of parthenolide at 37 °C for 60 min
and analyzed by immunoblotting as described above.
Assay of ASC Pyroptosome Formation in Macrophages—
Macrophages were seeded in 6-well plates (2  106 cells/well)
and then treatedwith vehicle or 5mMATP for different periods
of time in serum-free Opti-MEM I for 45 min. In some exper-
iments,macrophages were treatedwith vehicle or inhibitors for
15 min, followed by 5 mM ATP in serum-free OPTI-MEM I
for 45 min. The culture supernatants were collected and used for
immunoblot analyses of secreted caspase-1 p20 as described
above. The cells were pelleted by centrifugation and resus-
pended in 0.5 ml of ice-cold buffer containing 20 mM HEPES-
KOH, pH 7.5, 150 mM KCl, 1% Nonidet P-40, 0.1 mM phenyl-
methylsulfonyl fluoride, and protease inhibitor mixture and
lysed by shearing 10 times through a 21-gauge needle. The cell
lysates were centrifuged at 6000 rpm for 10 min at 4 °C. The
pellets were washed twice with phosphate-buffered saline and
then resuspended in 500 l of phosphate-buffered saline. The
resuspended pellets were cross-linked with fresh disuccinimi-
dyl suberate (2mM) for 30min as described (17) and pelleted by
centrifugation at 6000 rpm for 10 min. The cross-linked pellets
were resuspended in 30 l of SDS sample buffer and fraction-
ated on 12% SDS-polyacrylamide gel, followed by immunoblot-
ting with anti-mouse ASC antibody.
Assay of NLRP3 ATPase Activity—NLRP3 was purified from
NG5 cells by immunoprecipitation with anti-FLAG M2-
agarose affinity gel. Anti-FLAG immunoprecipitate from
Nlrp3/ cells was used as a negative control. NLRP3 ATPase
activity wasmeasured by assaying the hydrolysis of [-32P]ATP
to [-32P]ADP by NLRP3 using TLC. NLRP3 was preincubated
with different concentrations of Bay 11-7082, parthenolide, or
vehicle control (DMSO) in a total volume of 40 l of reaction
buffer (25mMTris-HCl, pH 7.5, 150mMNaCl, 10mMMgCl2, 1
mM EDTA, 1 mM phenylmethylsulfonyl fluoride, and protease
inhibitor mixture) for 30 min prior to addition of 0.1 M
[-32P]ATP (3000 Ci/mmol) and 1mMdithiothreitol (Research
Products International) for an additional 2 h. The reactions
were quenched by addition of an equal volume of TLC devel-
opment solvent (1 M formic acid and 0.5 M LiCl). A total of 2 l
from each reaction mixture was spotted on a polyethylene-
imine-cellulose TLC plate and developed with TLC develop-
ment solvent in a TLC chamber. The hydrolysis of [-32P]ATP
to [-32P]ADP was visualized by exposing the TLC plate to
x-ray film.
Mass Spectrometry—Recombinant active caspase-1 was ex-
pressed in bacteria with an N-terminal His6 tag and subse-
quently purified according to established procedures on Talon
metal affinity resin. The purified protein was incubated with
parthenolide (5 M) in buffer containing 20 mM HEPES-KOH,
pH 7.5, 5 mM MgCl2, and 0.5 mM EGTA for 1 h at 37 °C. The
parthenolide-modified proteinwas then fractionated by SDS-PAGE.
Gel bands corresponding to caspase-1 p20 were excised and
destained in 25 mM ammonium bicarbonate in 50% acetoni-
trile. After destaining, gel pieces were dehydrated with acetoni-
trile, reduced with 10 mM dithiothreitol, and alkylated with 55
mM iodoacetamide (GEHealthcare). Gel pieceswere oncemore
dehydrated before being digested with trypsin overnight at
37 °C. The tryptic peptides were extracted twice with 50% ace-
Inflammasome Inhibition by Parthenolide and Bay 11-7082
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tonitrile and 5% formic acid. The combined peptides were then
dried on a centrifuge evaporator and reconstituted in 0.1% tri-
fluoroacetic acid. Tryptic peptides were analyzed bymass spec-
trometry according to established procedures (see supplemen-
tal “Experimental Procedures”).
LDH Release Assay—NG5 macrophages were treated with
parthenolide and Bay 11-7082-related compounds for 10 min,
followed by ATP (5 mM) for 30 min. The culture supernatants
were collected and assayed for LDH activity with the CytoTox
96 LDH release kit (Promega) following the manufacturer’s
protocols.
RESULTS
Parthenolide and Bay 11-7082 Are Potent Inhibitors of the
Inflammasome—We have shown recently that NF-B activa-
tion in bone marrow macrophages by ligands of Toll-like or
cytokine receptors is required for induction of NLRP3 protein
expression but not sufficient for its activation (15). A second
stimulus such as ATP or nigericin is required for NLRP3
inflammasome activation. Consistent with these observations,
inhibition of NLRP3 up-regulation by pretreatment of macro-
phages with the protein synthesis inhibitor cycloheximide or
the NF-B inhibitor Bay 11-7082 (or Bay 11-7085) before LPS
priming abrogates caspase-1 activation by ATP (15, 18). Sur-
prisingly, additional investigations of the effect of different
NF-B inhibitors onNLRP3 inflammasome activation revealed
that two NF-B inhibitors, parthenolide and Bay 11-7082,
which are thought to selectively block the IKK kinase activity,
were still able to block the activation of the NLRP3 inflamma-
some even when these inhibitors were added to the cells after
LPS priming and just before ATP
stimulation (Fig. 1A, left panels).
This effect was not observed with
other NF-B inhibitors that selec-
tively inhibit the IKK kinase activ-
ity (IMD0354 and SC514) or with
MG132, which inhibits NF-B by
blocking the degradation of IB
(Fig. 1A, right panels), indicating
that inhibition of IKK kinase activ-
ity orNF-B activity is not sufficient
to block activation of the NLRP3
inflammasome by ATP in LPS-
primed macrophages. These results
indicate that parthenolide and Bay
11-7082 inhibit activation of the
NLRP3 inflammasome in LPS-
primed macrophages independent
of their effect on NF-B activation.
To further demonstrate that par-
thenolide and Bay 11-7082 inhibit
caspase-1 activation by the NLRP3
inflammasome independent of their
effect on NF-B activation, we
tested the effect of these drugs on
ATP-induced caspase-1 activation
in a stable Nlrp3/ bone marrow
macrophage cell line (designated
NG5) that constitutively expresses NLRP3 under the control of
amurine stem cell virus promoter. As observed previously (15),
stimulation of NG5 cells with ATP alone activated the NLRP3
inflammasome without prior priming with LPS (Fig. 1B). Con-
sistent with the results obtained with primary macrophages,
treatment with parthenolide or Bay 11-7082 completely inhib-
ited ATP-induced caspase-1 activation in NG5 cells (Fig. 1C).
In contrast, treatment with the NF-B inhibitors IMD0354,
SC514, andMG132 or the protein synthesis inhibitor cyclohex-
imide had no effect on ATP-induced caspase-1 activation in
these cells (Fig. 1C), further confirming that inhibition of
IKK kinase activity, NF-B, or protein synthesis does not
affect activation of the NLRP3 inflammasome by ATP. Par-
thenolide and Bay 11-7082 also inhibited nigericin-induced
and MSU-induced caspase-1 activation by the NLRP3
inflammasome in NG5 cells (Fig. 2A and supplemental
Fig. 1), indicating that these compounds target a common
signaling component(s) downstream of the P2X7 receptor,
which mediates NLRP3 activation by ATP. Parthenolide and
Bay 11-7082 were also able to inhibit MSU-induced
caspase-1 activation in human THP-1 macrophages (Fig.
2B), indicating that their inflammasome inhibitory effect is
not restricted to mouse macrophages.
Bay 11-7082 Is a Selective Inhibitor of the NLRP3 Inflam-
masome, whereas Parthenolide Can Inhibit Multiple In-
flammasomes—To determine whether the effect of parthe-
nolide and Bay 11-7082 on caspase-1 activation is specific for
theNLRP3 inflammasome orwhether these drugs could inhibit
other inflammasome signaling pathways, we stimulated
Nlrp3/ macrophages with anthrax lethal toxin (protective
FIGURE 1. Parthenolide and Bay 11-7082 inhibit the NLRP3 inflammasome. A, immunoblots of caspase-1
and IL-1 in culture supernatants (Sup; upper and middle panels) or caspase-1 in cell lysates (lower panels) of
LPS-primed primary wild-type bone marrow-derived macrophages treated with Bay 11-7082 (Bay; 12 M),
parthenolide (Parth; 10 M), MG132 (10 M), IMD0354 (IMD; 10 M), or SC514 (10 M) for 15 min, followed by
5 mM ATP for 45 min as indicated. B, immortalized NLRP3 knock-out (NLRP3-KO; left panels) or NLRP3-
reconstituted NG5 macrophages (right panels) were left untreated or stimulated with LPS (500 ng/ml) for
5 h and subsequently treated with 5 mM ATP for 45 min as indicated. Immunoblots of caspase-1 in culture
supernatants (upper panels) or cell lysates (middle panels) are shown. Immunoblots of NLRP3 in cell lysates
are shown in the lower panels. C, immunoblots of caspase-1 in culture supernatants of NG5 macrophages
treated with vehicle (DMSO), Bay 11-7082 (12M), parthenolide (10M), MG132 (10M), IMD0354 (10M),
SC514 (10 M), or cycloheximide (Cyclo; 20 M) for 15 min, followed by 5 mM ATP for 45 min as indicated.
Procasp1, procaspase-1.
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antigen/lethal factor), which activates the NLRP1 (NALP1)
inflammasome (19), in the presence or absence of these drugs.
As shown in Fig. 2C, parthenolide inhibited protective antigen/
lethal factor-induced caspase-1 activation, whereas Bay
11-7082 had no effect. Interestingly, parthenolide completely
inhibited Salmonella-induced caspase-1 activation through the
NLRC4 (IPAF) inflammasome, whereas Bay 11-7082 showed a
partial inhibitory effect (Fig. 2D). This partial inhibition might
be due to possible side effect of the drug on Salmonella uptake
by macrophages. These results suggest that Bay 11-7082 selec-
tively inhibits the NLRP3 inflammasome pathway, whereas
parthenolide inhibits the activity of multiple inflammasome
pathways.
Parthenolide Is a Direct Inhibitor of Caspase-1—Parthenol-
ide is a potent natural anti-inflammatory drug derived from the
medicinal plant feverfew. The anti-inflammatory activity of
parthenolide has been attributed to its ability to alkylate critical
cysteine residues in IKK and p65 (20–23), but its ability to
inhibit the activity ofmultiple inflammasomes at lowmicromo-
lar concentration (Figs. 1 and 2) suggests that it may act on a
target that is common to all inflammasome signaling pathways.
Because caspase-1 is the only component that is common to all
inflammasomes, we explored whether parthenolide might
directly inhibit in vitro caspase-1 activation in THP-1 lysates.
As shown in Fig. 3A, incubation of THP-1 cell lysates at 37 °C
resulted in caspase-1 activation, whichwas inhibited by parthe-
nolide but not by Bay 11-7082. Activation of caspase-1 in this
assay ismediated by self-oligomerization of ASC and formation
of the ASC pyroptosome (13), so we incubated preformed ASC
pyroptosomes with procaspase-1 to assess whether partheno-
lide blocks caspase-1 activation directly or indirectly via inhibi-
tion of ASC oligomerization. As expected, ASC pyroptosomes
activated caspase-1, which cleaved pro-IL-1 to produce the
active IL-1 cytokine, in the
absence of parthenolide but not in
its presence (Fig. 3B), indicating
that parthenolide inhibits caspase-1
activity downstream of ASC oligo-
merization under these conditions.
To provide additional support for
the direct effect of parthenolide on
caspase-1 activity, we incubated
purified active caspase-1 with pro-
IL-1 in the presence of increasing
amounts of parthenolide. The
upward shift in the migration of the
p20 subunit of caspase-1 on a dena-
turing gel demonstrates that par-
thenolide directly alkylates the p20
subunit of caspase-1, which likely
accounts for its ability to inhibit
proteolysis of pro-IL-1 (Fig. 3C).
This parthenolide-induced shift in
themigration of caspase-1 p20 was
also observed in Salmonella-in-
fected cells when parthenolide was
added 30 min after infection (Fig.
3D), indicating that parthenolide
can cross the plasma membrane and covalently inactivate
the p20 subunit of caspase-1, as was observed in the in vitro
cell-free system. Together, these results suggest that parthe-
nolide inactivates caspase-1 by alkylation of the p20 subunit.
To further investigate the mechanism of caspase-1 inhibi-
tion by parthenolide, we incubated recombinant bacterially
produced wild-type caspase-1 with or without parthenolide,
fractionated the protein by SDS-PAGE, excised the modified
caspase-1 band (Fig. 3E, lane 2), and subjected it to tryptic
digestion, followed by mass spectrometry. This analysis
revealed that tryptic fragments containing the catalytic
Cys285 of caspase-1 p20 are covalently modified by parthe-
nolide (supplemental Fig. 2A). In addition, Cys136, Cys169,
and Cys244 of caspase-1 p20 were also modified by partheno-
lide. These results provide direct evidence that parthenolide
can inactivate caspase-1 by direct alkylation of the active site
(Cys285) and most of the conserved cysteines on the p20
subunit. Consistent with these results, site-directed mu-
tagenesis of the parthenolide-modified cysteines to alanines
abolished the parthenolide-induced upward shift in the
migration of the p20 subunit of caspase-1 on a denaturing
SDS-polyacrylamide gel (supplemental Fig. 2B).
Bay 11-7082 and Parthenolide Inhibit NLRP3-induced ASC
Pyroptosome Formation by Inhibiting NLRP3 ATPase Activity—
BecauseBay 11-7082 can inhibit caspase-1 activation byNLRP3
stimuli in macrophages but does not inhibit the autocatalytic
activation of caspase-1 in vitro or in cells (Fig. 3, A and D), the
compound must interfere with NLRP3-mediated ASC oligo-
merization or a component of the upstream signaling pathway.
To demonstrate this directly, we devised a simple biochemical
assay that allows the determination of NLRP3-induced ASC
oligomerization in stimulatedmacrophages. This assay is based
on our previous observation that activation of the NLRP3
FIGURE 2. Bay 11-7082 is a selective inhibitor of the NLRP3 inflammasome, whereas parthenolide can
inhibit multiple inflammasomes. A and B, immunoblots of caspase-1 in culture supernatants of NG5macro-
phages (A) and human THP-1 macrophages (B) treated with vehicle (DMSO), Bay 11-7082 (Bay; 12 M), or
parthenolide (Parth; 10M) for 15min, followedby nigericin (Nig; 10M) for 45min orMSU for 5 h as indicated.
C and D, immunoblots of caspase-1 in culture supernatants of Nlrp3/ macrophages treated with vehicle
(DMSO), Bay 11-7082 (12 M), or parthenolide (10 M) for 15 min, followed by anthrax lethal toxin protective
antigen/lethal factor (PA/LF) or Salmonella infection (Sal; multiplicity of infection of 20) for 3 h as indicated.
Procasp1, procaspase-1.
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inflammasome by NLRP3 stimuli triggers formation of a large
ASC oligomer termed the ASC pyroptosome (see Fig. 7 and
Ref. 13), which is composed of oligomerized ASC dimers.
The ASC pyroptosome can be isolated from stimulated cells
by low speed centrifugation and quantified by immunoblot-
ting. As shown in Fig. 4A (left andmiddle panels), ATP stim-
ulation induced ASC pyroptosome formation within 5 min
in NG5 macrophages, which express NLRP3, but not in
parental Nlrp3/ macrophages, indicating that NLRP3
activity is required for ASC pyroptosome formation. Similar
results were obtained in LPS-primed wild-type macrophages
(supplemental Fig. 3) (13). Pretreatment of NG5 cells with
Bay 11-7082 inhibited ASC pyroptosome formation (Fig. 4A,
right panels), Similarly, pretreatment of NG5 cells with par-
thenolide also inhibited ASC pyroptosome formation (Fig.
4A, right panels). These results indicate that Bay 11-7082 and
parthenolide inhibit the NLRP3 inflammasome at the level of
NLRP3 or upstream of it.
NLRP3 is an ATPase, and its ATPase activity is required to
recruit and oligomerize ASC and activate caspase-1 (24). To
test whether Bay 11-7082 or parthenolide can inhibit NLRP3
ATPase activity, we preincubated purified NLRP3 with Bay
11-7082 or parthenolide and then assayed its ability to
hydrolyze [-32P]ATP to [-32P]ADP. As shown in Fig. 4B,
both parthenolide and Bay 11-7082 inhibited the ATPase
activity of NLRP3 in a dose-dependent manner. Collectively,
our results suggest that Bay 11-7082 inhibits activation of the
NLRP3 inflammasome, possibly by inhibiting its ATPase
activity. Interestingly, in addition to its ability to directly
inhibit the catalytic activity of caspase-1, parthenolide also
inhibited NLRP3-induced ASC oligomerization by inhibiting
NLRP3ATPase activity, indicating that parthenolide inhibits
multiple components of inflammasome pathways, which
helps to rationalize its potent anti-inflammatory activity
in vivo.
The Vinyl Sulfone Group of Bay 11-7082 Is Required for Inhi-
bition of the NLRP3 Inflammasome—On the basis of reports of
covalent modification of proteins and nucleic acids with vinyl
sulfones and acrylonitriles (25–27), we hypothesized that the
trans-vinyl sulfone nitrile functional group in Bay 11-7082
might irreversibly inhibit activation of the NLRP3 inflamma-
some via alkylation of one or more nucleophilic residues. To
assess whether alkylation is important for inhibitory activity,
we first preincubated Bay 11-7082 with free glutathione or
L-cysteine and then tested the ability of both pretreated and
untreated Bay 11-7082 to inhibit caspase activation. Preincuba-
tion of Bay 11-7082 with glutathione or L-cysteine abrogated
NLRP3 inhibitory activity (Fig. 5A, left panel), which is consis-
tent with an inhibition mechanism involving target alkylation.
To explore structure-activity relationships governing
target alkylation by Bay 11-7082, we assayed caspase activa-
tion by ATP (Fig. 5C) and activation of NF-B by LPS (Fig.
5D) in NG5 macrophages in the presence of seven structurally
related compounds (Fig. 5B): (2E)-3-[(4-tert-butylbenzene)-
sulfonyl]prop-2-enenitrile (Bay 11-7085), (E)-2-iodo-
3-(4-methylphenyl)sulfonylprop-2-enenitrile (IMPSPN),
3-[(4-methylbenzene)sulfonyl]propanenitrile (MBSPN), 1-(3-
chloroprop-1-enylsulfonyl)-4-methylbenzene (CPSMB), 1-(eth-
enylsulfonyl)-4-methylbenzene (ESMB), phenyl vinyl sulfone
(PV-sulfone), and phenyl vinyl sulfide (PV-sulfide). This series
of compounds provides insight into the role of the olefin in
alkylation (MBSPN), the relative significance of the sulfone and
nitrile substituents in determining the site of nucleophilic
attack (ESMB, CPSMB, PV-sulfone, and PV-sulfide), and the
effect of steric bulk on inhibitory activity (IMPSPN and Bay
11-7085). In MBSPN, the prop-2-enenitrile of Bay 11-7082 is
reduced, which eliminates unsaturation between the sulfone
and nitrile functional groups. The resulting sulfonylpropaneni-
trile fails to inhibit caspase-1 andNF-B activation asmeasured
by procaspase-1 processing and pro-IL-1 induction, respec-
tively (Fig. 5,C andD), demonstrating that the olefin is essential
for inhibition and suggesting that alkylation results from
Michael addition at either C-2 or C-3 of Bay 11-7082. To fur-
ther clarify the site of nucleophilic attack, the inhibitory poten-
cies of two compounds lacking the nitrile substituent were
assessed. Replacing the nitrile in Bay 11-7082 with either
hydrogen (ESMB and PV-sulfone) or a chloromethyl substitu-
ent (CPSMB) resulted in compounds that were still able to
FIGURE 3. Parthenolide is a direct inhibitor of caspase-1. A, lysates from
THP-1 cells (10 mg/ml) were incubated at 4 °C or activated at 37 °C in the
presence of DMSO, Bay 11-7082 (Bay; 12 M), or parthenolide (Parth; 10 M)
for 60 min. The lysates were analyzed by Western blotting with anti-human
caspase-1 antibody. B, purified preformed ASC pyroptosomes were incu-
batedwith N-terminally FLAG-tagged procaspase-1 (Procasp1) and pro-IL-1
in the presence of DMSO or the indicated concentrations of parthenolide at
37 °C for 1 h. The total reaction mixtures were fractionated by SDS-PAGE,
followed by Western blotting with anti-FLAG (upper panel) and anti-IL-1
(lower panel) antibodies. C, purified recombinant mature human caspase-1
was incubatedwith pro-IL-1 in thepresence of the indicated concentrations
of parthenolide at 37 °C for 1 h. The total reactionmixtures were fractionated
by SDS-PAGE, followed by Western blotting with anti-human caspase-1
(upper panel) and anti-IL-1 (lower panel) antibodies.D, shown is an immuno-
blot of caspase-1 in culture supernatants of Nlrp3/ macrophages treated
with vehicle (DMSO), Bay 11-7082 (12M), or parthenolide (10M) for 30min
following Salmonella infection (Sal) as indicated. The infectionwas continued
for a total of 3h. E, shown is aCoomassie Blue-stainedSDS-polyacrylamidegel
of purified recombinant caspase-1 left untreated (lane 1) or treated with 10
M parthenolide (lane 2) for 1 h at 37 °C. The gel shows the processed p20
subunit of caspase-1.
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inhibit caspase-1 and NF-B activation, albeit with reduced
potency. However, reducing the benzylic sulfone (OSO) to
a thioether produced a compound (PV-sulfide) that failed to
inhibit caspase-1 activation, indicating that the sulfone
group is also essential for inhibition. Taken together, these
results strongly suggest that Bay 11-7082 inhibits the NLRP3
inflammasome by alkylation via Michael addition of target
nucleophiles at C-2 of Bay 11-7082. Addition of steric bulk at
C-2 (IMPSPN) or on the benzyl substituent (Bay 11-7085)
had no effect on inhibition, suggesting that neither of these
positions is important for productive interaction with the
target.
Parthenolide and Phenyl Vinyl Sulfone Compounds Inhibit
NLRP3-induced Pyroptotic Cell Death—Treatment of LPS-
primedmacrophages with NLRP3 stimuli such as ATP induces
rapid caspase-1-dependent pyroptotic cell death, which can
be inhibited by extracellular KCl and the type 2 diabetes drug
glyburide (13, 28). This (LPS plus ATP)-induced cell death is
dependent on caspase-1 (13) and NLRP3 (28), as macro-
phages lacking caspase-1 or NLRP3 remain viable in the pres-
ence of LPS plusATP. To determine
the effect of parthenolide and phe-
nyl vinyl sulfone compounds on the
viability ofNG5 cells, we assayed the
activity of LDH released in the cul-
ture supernatants of cells after pre-
treatment with drugs for 10 min,
followed by ATP treatment for 30
min (Fig. 6). Consistent with their
ability to inhibit NALP3-mediated
caspase-1 activation, parthenolide
and the phenyl vinyl sulfone-related
compounds Bay 11-7082, Bay
11-7085, IMPSPN, CPSMB, and
ESMB all inhibited LDH release in a
dose-dependent manner (Fig. 6,
A–F). Additionally, cells treated
with these drugs looked morpho-
logically normal by microscopic
examination (data not shown). In
contrast, drugs such asMBSPN (Fig.
6G), which does not target the
NLRP3 inflammasome, did not
inhibit LDH release. The observed
decrease in LDHactivity in the pres-
ence of parthenolide or phenyl vinyl
sulfone derivatives (Bay 11-7082
and Bay 11-7085) is not due to inhi-
bition of LDH activity by these
drugs because LDH activity in the
culture supernatants of ATP-
treated NG5 cells was not changed
when these compounds were added
to the assay reactions (Fig. 6H).
Together, these results indicate that
parthenolide and phenyl vinyl sul-
fone-related compounds not only
inhibit caspase-1 activation but also
block macrophage cell death, which provides further support
for previous genetic findings that rapid ATP-induced cell death
in primed macrophages is dependent on NALP3 and caspase-1
(13, 28).
DISCUSSION
The NLRP3 inflammasome is an important component of
the innate immune response against a broad range of microbial
and self-generated danger signals, including bacterial pore-
forming toxins, ATP, andMSU crystals (Fig. 7) (1). The molec-
ular mechanism of activation of the NLRP3 inflammasome by
these diverse stimuli is still unclear, but evidence suggests that
NLRP3 is activated by a two-step mechanism. In the first step,
known as the priming step, NLRP3 is transcriptionally up-reg-
ulated by NF-B-inducing stimuli such as ligands of the Toll-
like receptors (15). However, the induction of NLRP3 protein
expression is not sufficient for its activation, and another tran-
scription-independent step (activation step) is required for
NLRP3 activation (15). This step is triggered by stimuli such as
ATP (which activates the P2X7 receptor), pore-forming toxins
FIGURE 4.Parthenolide andBay 11-7082 inhibit theNLRP3 inflammasomeby targeting its ATPase activ-
ity. A, NLRP3 knock-out (NLRP3-KO) and NG5macrophages were treated with ATP for the indicated periods of
time (left and middle panels) or were treated with vehicle (DMSO), Bay 11-7082 (Bay; 12 M), or parthenolide
(Parth; 10 M) for 15 min, followed by ATP (right panels) as indicated. The culture media were immunoblotted
(IB) with anti-caspase-1 antibody (lower panels). The cells were lysed, and the resulting 6000-rpm cell pellets
were cross-linked with disuccinimidyl suberate. The cross-linked pellets (upper panels) and cell lysates (middle
panels) were immunoblotted with anti-ASC antibody. B, shown is the ATPase activity of immunoprecipitated
recombinant NLRP3 and control immunoprecipitates in the presence of increasing concentrations of Bay
11-7082 or parthenolide as indicated. Procasp1, procaspase-1.
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such as nigericin, or phagocytosis of MSU crystals. Several
studies have shown that these stimuli lead to the generation of
reactive oxygen species, potassium efflux, and disruption of
lysosomes, which results in the release of lysosomal cathepsin B
into the cytoplasm (reviewed in Ref. 1). A recent study provided
evidence that reactive oxygen species generated by NLRP3
FIGURE 5. The vinyl sulfone of Bay 11-7082 is required for inhibition of the NLRP3 inflammasome. A, immunoblots of caspase-1 in culture supernatants
of NG5 macrophages treated with Bay 11-7082 (Bay) and related compounds containing phenyl vinyl sulfone (B) in the presence or absence of glutathione
(Glut) or L-cysteine for 15 min, followed by ATP (5 mM) for 45 min. B, structures of Bay 11-7082 and related compounds used in the experiments in C and D.
C, immunoblots of caspase-1 in culture supernatants of NG5macrophages treated with the indicated concentrations of Bay 11-7082 and related compounds
for 15 min, followed by ATP (5 mM) for 45 min. D, immunoblots of NF-B-regulated pro-IL-1 in cell lysates of NG5 macrophages treated with DMSO, Bay
11-7082, CPSMB, orMBSPN compounds (left panels) orMBSPN, IMPSPN, or ESMB compounds (right panels) for 15min, followedby LPS for 5 h.-Actinwas used
as an internal loading control (lower panels). Procasp1, procaspase-1.
FIGURE 6. InhibitionofATP-induced cell deathbyparthenolide andBay11-7082-related compounds inNG5macrophages.A–G, cell deathwas assayed
bymeasuring thepercentages of LDHactivity released in culture supernatants of NG5macrophages (% cytotoxicity) treatedwith the indicated concentrations
of parthenolide (Parth; A), Bay 11-7082 (B), and the indicated Bay 11-7082-related compounds (C–G) for 10min, followed by ATP (5 mM) for 30min. Each point
represents the average of three experiments (n 3).H, shown is the LDH activity in culture supernatants of NG5 cells treatedwith ATP for 1 h. The LDH activity
(A490 units) was assayed in the presence of DMSO, parthenolide (20M), Bay 11-7082 (20M), or Bay 11-7085 (20M). Note that these drugs did not affect LDH
enzymatic activity (H).
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stimuli activate NLRP3 by promoting its association with
TXNIP (thioredoxin-interacting protein) (29). Once activated,
NLRP3 undergoes self-oligomerization to form a molecular
platform (24), which recruits the adaptor protein ASC. This
step leads to self-oligomerization of ASC into a very large
supramolecular structure called the pyroptosome (13), which
recruits and activates procaspase-1, leading to the processing of
pro-IL-1 and pro-IL-18 into the active pro-inflammatory
cytokines IL-1 and IL-18, respectively. Activated caspase-1
also triggers a form of cell death called pyroptosis (30).
The NLRP3 inflammasome activity is abnormally elevated in
many human inflammatory diseases, including gout, silicosis,
neurodegeneration, and genetically inherited periodic fever
syndromes (5–8). Therefore, there is considerable interest in
the identification of effective therapeutics that selectively
inhibit the NLRP3 inflammasome pathway. In this work, we
have identified parthenolide, Bay 11-7082, and structurally
related vinyl sulfones as the first potential smallmolecule inhib-
itors that target the NLRP3 inflammasome pathway at multiple
levels (Fig. 7). Parthenolide, a plant sesquiterpene lactone, has
been used extensively as an herbal remedy for treatment of
multiple inflammatory diseases, including fever, migraine,
arthritis, psoriasis, and atherosclerosis, with few mild side
effects (31–33). Recent studies have shown that treatment with
parthenolide improves the survival of mice challenged with
LPS, retards atherosclerotic lesions in apoE mice, and amelio-
rates bladder inflammation in a rat cystitis model (34–36).
These therapeutic effects have been attributed mostly to inhi-
bition of NF-B by parthenolide. However, in addition to its
anti-NF-B activity, our results now clearly demonstrate that
parthenolide is a potent inhibitor of multiple inflammasomes.
We have shown for the first time that parthenolide is a direct
inhibitor of the protease activity of caspase-1 and is also an
inhibitor of the ATPase activity of NLRP3. The change in
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FIGURE 7.Model illustrating the signaling pathways involved in activation of the NLRP3 inflammasome. See “Discussion” for more details. TLR, Toll-like
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migration of the p20 subunit of caspase-1 on SDS-PAGE fol-
lowing incubation with parthenolide indicates that the com-
pound inhibits caspase-1 activity by alkylating critical cysteine
residues in the p20 subunit. Indeed, mass spectrometry identi-
fied the active-siteCys285 of caspase-1 as one of the p20 cysteine
residues that aremodified by parthenolide. Similarly, alkylation
is likely to be responsible for the inhibitory effect of partheno-
lide on NLRP3-dependent ATPase activity.
Unlike parthenolide, Bay 11-7082 and related compounds
appear to bemore selective for theNLRP3 inflammasomepath-
way comparedwith other inflammasomepathways becauseBay
11-7082 did not inhibit caspase-1 activity in vitro and did not
affect activation of the NLRP1 inflammasome by anthrax lethal
toxin. Because NLRP1 also possesses an ATPase activity that is
important for its ability to activate caspase-1 (37), these obser-
vations indicate that Bay 11-7082 does not inhibit the NLRP1
ATPase activity. The partial inhibitory effect of Bay 11-7082 on
Salmonella-induced NLRC4 inflammasome activation could
be due to a toxic effect of Bay 11-7082 on Salmonella itself or
might be due to other possibilities such as inhibition of bacterial
uptake by macrophages, partial inhibition of NLRC4 ATPase
activity itself, or partial inhibition of a signaling component
upstream of NLRC4. However, like parthenolide, Bay 11-7082
and related phenyl vinyl sulfones inhibit their target proteins
most likely through alkylation mediated by attack of essential
nucleophilic residues such as cysteines on the vinyl sulfone
group. Indeed, the inhibition of ATP-induced caspase-1 activa-
tion in NG5 macrophages by parthenolide or Bay 11-7082
could not be reversed by washing off the drugs, which is con-
sistent with an irreversible covalent inactivation mechanism
(supplemental Fig. 4). Furthermore, preincubation of Bay
11-7082 and the related phenyl vinyl sulfone compounds IMP-
SPN and ESMBwith glutathione abrogated their NLRP3 inhib-
itory activity (Fig. 5A), which is consistent with an inhibition
mechanism involving target alkylation.
A recent study clearly demonstrated inhibition of theNLRP3
inflammasome by the type 2 diabetes drug glyburide (28). How-
ever, glyburide was 10-fold less effective than Bay 11-7082
and did not affect theATPase activity ofNLRP3, indicating that
it is not a direct inhibitor of NLRP3 but rather acts upstream of
NLRP3 and downstream of the P2X7 receptor to block NLRP3
inflammasome activation. In contrast to glyburide, we have
provided in vitro biochemical evidence that Bay 11-7082 inhib-
its the ATPase activity of NLRP3, which is required for its acti-
vation (24), suggesting that the inflammasome inhibitory effect
of Bay 11-7082 and related vinyl sulfone compounds might be
the result of inhibition of theATPase activity ofNLRP3 by these
compounds. However, it is still possible that these compounds,
like glyburide, inhibit a signaling component upstream of
NLRP3. Recent structural studies showed that phenyl vinyl sul-
fones or phenyl vinyl sulfonates are irreversible mechanism-
based inhibitors of protein-tyrosine phosphatases (38). Because
of their structural similarity to phosphotyrosines, these com-
pounds bind to the active site of protein-tyrosine phosphatases
with high affinity and inactivate their active-site cysteine by a
mechanism involving a Michael addition of the -thiol to the
terminal carbon of the vinyl group (38). Remarkably, we found
that phenyl vinyl sulfonate is as potent as Bay 11-7082 in inhib-
iting the NLRP3 inflammasome activity (supplemental Fig. 5),
suggesting the possibility that these drugsmight also target crit-
ical, still unidentified protein-tyrosine phosphatases in the
NLRP3 and NF-B pathways. Phenyl vinyl sulfone derivatives
are also irreversible inhibitors of cysteine proteases such as
cathepsins (39–41), raising the possibility that these com-
pounds might also target a critical cysteine protease upstream
ofNLRP3.Notably, the lysosomal cysteine protease cathepsin B
has been previously suggested to be involved in the activation of
the NLRP3 inflammasome (6, 42–44). However, our results
using the specific cathepsin B inhibitor CA-074-Me or the
broad-spectrum cysteine protease inhibitor E-64 showed that
neither of these two compounds was able to inhibit caspase-1
activation by ATP (supplemental Fig. 6). Consistent with these
results, a recent study demonstrated that a pan-cathepsin
inhibitor, as well as specific cathepsin B inhibitors, did not
impair caspase-1 activation induced by LPS plus ATP (45).
Based on these observations, the inhibition of the NLRP3
inflammasome by Bay 11-7082 and related vinyl sulfones/sul-
fonates is not likely to be due to inhibition of cathepsins.
Finally, recent preclinical trials in mice and dogs using vinyl
sulfone derivatives as antiparasitic agents (46) have shown that
these drugs are non-mutagenic and well tolerated and display
an acceptable pharmacokinetic profile. Therefore, the identifi-
cation of Bay 11-7082 and related vinyl sulfone/sulfonate com-
pounds as effectiveNLRP3 inflammasome inhibitors provides a
framework for the future design of effective anti-inflammatory
vinyl sulfone/sulfonate derivatives that selectively target the
NLRP3 inflammasome pathway for the treatment of many
inflammatory diseases, as well as for the design of Bay 11-7082
and vinyl sulfone/sulfonate-based probes to characterize the
critical components involved in the activation of the NLRP3
inflammasome by various stimuli.
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